

Section I. (Amendments to the Specification)

Please amend the specification as follows:

On page 1, please insert below the title, before the heading "TECHNICAL FIELD," the following new paragraph:

PRIORITY CLAIM AND CROSS-REFERENCE TO RELATED APPLICATIONS

This application is filed under the provisions of 35 U.S.C. §371 and claims the benefit of priority of International Patent Application No. PCT/KR2005/000356, filed 4 February 2005, which in turn claims priority of Korean Patent Application No.10-2004-0007321, filed 4 February 2004. The disclosures of all said applications are hereby incorporated herein by reference in their respective entireties.

On page 9, please replace the paragraph beginning at line 15 ("FIG. 4 graphically shows the results...") with the following new replacement paragraph:

FIG 4 graphically shows the results of enzyme-linked immunosorbent assay (ELISA) for IgG antibody titers against CPV VP2-1 and CPV VP2-2 antigens in the serum of mice orally and rhinally administered with a Lactobacillus casei strain which has been transformed with each of the inventive surface expression vector pHCE2LB: pgsA: VP2-1 and pHCE2LB: pgsA: VP2-2 and confirmed to have an epitope expressed on its surface. ~~"A" represents IgA antibody titer in the oral administration group, and "B" represents IgA antibody titer in the rhinal administration group.~~

On page 12, please replace the paragraph beginning at line 4 ("VP2-1 having an amino acid length of 153...") with the following new replacement paragraph:

VP2-1 having an amino acid length of 153 (2nd-[[153rd]] 155th amino acids) was named "CPV VP2-1", and a fragment having an amino acid length of 270 (252nd-522nd amino acids) was named "CPV VP2-2.